###### Strengths and limitations of this study

-   Ventricular remodelling following tanscatheter aortic valve implantation (TAVI) has not been studied much, to date. This is the first study to prospectively explore the impact of renin-angiotensin system (RAS) modulation in this scenario; in addition, the consequences of RAS blockade in major outcomes of patients harbouring a TAVI device will also be explored.

-   The design as a randomised 1:1 open label study (ramipril vs standard care) and the vast experience of the participating institutions will confer great validity to future findings.

-   Also, the central analysis of cardiac magnetic resonance examinations will increase the accuracy of measurements and, therefore, validity.

-   As a limitation, bias could be derived from the unblinded nature of the study for the treating specialist; external monitoring will be performed to control this risk.

Introduction {#s1}
============

Aortic stenosis (AS) is the result of a slow progressive disease related to atherosclerosis, inflammation, haemodynamic factors and active calcification.[@R1] It presents an age-related growing incidence as a result of these degenerative mechanisms and, therefore, it has a great impact in the ageing population of developed countries.[@R2] In parallel, old patients often present an increased risk for conventional surgery due to frailty and comorbidities. For this reason, in the last decade the use of transcatheter aortic valve implantation (TAVI) as a less invasive alternative to treat AS has increased exponentially.[@R3]

Several studies have demonstrated the benefits of TAVI in high-risk and intermediate-risk patients,[@R3] but clinical practice has rapidly moved forward in this scenario, often beyond current evidence and despite a number of unanswered questions remaining, that include the identification of factors with potential impact in long-term outcomes.[@R8] In particular, the presence of fibrosis and myocardial hypertrophy in patients with AS has been related to worse prognosis especially if they persist once the valvular obstruction has been treated.[@R9] Therefore, better outcomes may be achieved with the use of strategies improving cardiac remodelling by reversing fibrosis and hypertrophy.[@R14] In this regard, renin-angiotensin system (RAS) blockade has been shown to have a positive impact in remodelling and in major clinical outcomes in alternative scenarios.[@R17] In particular, its use in patients with AS and in those undergoing conventional surgery, has demonstrated consistent benefit.[@R25] However, there are no data regarding the effects of this therapy for TAVI recipients.

The RAS blockade after TAVI (RASTAVI) Study (<http://www.ClinicalTrials.gov> NCT03201185) aims to investigate the effect of adding ramipril to the standard care in patients successfully treated with TAVI in terms of ventricular remodelling as assessed by cardiac magnetic resonance (CMR) and in the main clinical outcomes.

Methods and analysis {#s2}
====================

The RASTAVI Study is a national, multicentre, open-label and randomised 1:1 trial aiming to determine the effect of ramipril on cardiac events, functional capacity and the evolution of cardiac remodelling on patients with AS undergoing TAVI. Online [supplementary files 1--3](#SP1 SP2 SP3){ref-type="supplementary-material"} show the official version of the protocol, the financial sources and the model consent form, respectively.

Patients across eight centres (summarised in [table 1](#T1){ref-type="table"}) will be randomised to receive conventional treatment or conventional treatment plus ramipril. Regular pathways exist to communicate important protocol modifications if any. Workflow has been schematically depicted in [figure 1](#F1){ref-type="fig"}. Briefly, after initial clinical evaluation to determine the suitability of the candidate, informed consent will be obtained by the investigators and standard baseline evaluation including transthoracic echocardiography, blood tests and 6-minutes walk test will be performed. After the TAVI procedure the patients will be randomised to receive either standard care or an initial dose of ramipril (2.5 mg). Titration of the ramipril dose will be performed at 1-month and 3 month follow-up visits aiming 10 mg daily if tolerated; in case there are symptoms related to dose increase, it will be reduced to the previous dose. Patients in the control group will not receive RAS inhibitors throughout the study; if their blood pressure is beyond recommended parameters (140/90 mm Hg) the physician responsible for the patient will administer any medication to control it except for RAS blockers.

###### 

RASTAVI Study expected recruitment

  --------------------------------------------------------------------------------------------------------------------------
  Centre                                            City         Country   Expected number of patients recruited (2 years)
  ------------------------------------------------- ------------ --------- -------------------------------------------------
  Hospital Clínico Universitario de Valladolid\     Valladolid   Spain     50
  (coordinating centre)                                                    

  Hospital General Universitario Gregorio Marañón   Madrid       Spain     50

  Hospital Universitario Puerta de Hierro           Madrid       Spain     35

  Hospital Universitario Virgen de la Victoria      Málaga       Spain     50

  Hospital Universitario Clínico San Carlos         Madrid       Spain     50

  Hospital Clínic de Barcelona                      Barcelona    Spain     35

  Hospital Universitari Vall d'Hebron               Barcelona    Spain     35

  Hospital Universitario de Vigo                    Vigo         Spain     35
  --------------------------------------------------------------------------------------------------------------------------

RASTAVI, renin-angiotensin system blockade after transcatheter aortic valve implantation.

![Schematic workflow for the RAS blockade after TAVI (RASTAVI) Study. 6-MWT: 6-min walk test; CMR, cardiac magnetic resonance; FU, follow-up; RAS, renin-angiotensin system; TAVI, transcatheter aortic valve implantation; TTE, transthoracic echocardiography. Note: telephonic 36-month follow-up visit is allowed.](bmjopen-2017-020255f01){#F1}

A baseline CMR will be performed and repeated at 1-year follow-up. Central analysis of all images will be performed by an independent unit ([www.icicorelab.es](www.icicorelab.es)). Main parameters to be recorded are summarised in [box 1](#B1){ref-type="boxed-text"}. The steering committee in the coordinating centre will determine adjudication of the responsibilities and events according to the criteria defined in the study protocol.Box 1Main clinical and imaging parameters that will be recorded for each patient1) Clinical evaluationAge, gender, height, weight, body mass index, body surface, cardiovascular risk factors, medications, familial and personal background, date of first diagnosis of aortic stenosis, former ischaemic cardiomyopathy, former cerebrovascular events, peripheral arterial disease, pulmonary disease, main symptoms (including NYHA class), arterial pressure, heart rate, murmurs, heart failure signs, quality of life questionnaire, frailty evaluation.ECG: sinus rhythm, atrial fibrillation, pacemaker, atrial or ventricular hypertrophy.Blood tests: haemoglobin, haematocrit, lipids, NT-proBNP, T-Tn, electrolytes, C reactive protein, creatinine, glomerular filtration rate.2) Transthoracic echocardiography (height, weight, arterial pressure and heart rate will be recorded)Left atrium: telediastolic diameters; telesystolic diameters.Basal interventricular septum and posterior wall width; LV mass.LV telediastolic and telesystolic volume, stroke volume, ejection fraction (Teicholz and Simpson).Aortic valve: peak velocity, peak and mean gradient and VTI for LVOT and aortic valve; LVOT diameter, estimated aortic valve area, presence and severity of aortic regurgitation (I/II/III), location of regurgitation (periprosthetic or intraprosthetic).Mitral valve: normal; degenerative; rheumatic; severity of regurgitation (I/II/III); mechanism of regurgitation (functional due to annular dilation/functional due to tenting/rheumatic/ degenerative); ERO.Tricuspid valve: TAPSE; lateral S wave; regurgitation; severity of regurgitation (I/II/III); systolic peak gradient between right ventricle and right atrium; dimensions of inferior vena cava and respiratory variations (no/less than 50% or more than 50%).Diastolic function parameters: E and A waves; E/A; deceleration time of E wave; isovolumetric relaxation time; E\' wave; A\' wave.3) Cardiac magnetic resonance (all exams will be performed with 1.5 Tesla systems, synchronised and during respiratory apnoea; height, weight, arterial pressure and heart rate will be recorded)Locators of three planes in the space (axial, coronal and sagittal) enclosing the entire cardiac area.Right and left ventricular function study: SSFP sequences (TrueFISP, bTFE, FIESTA): a) four-chamber view (horizontal long-axis), two-chamber view (vertical long-axis) and complete short-axis; b) 30 phases, 8 mm width, 0 mm gap.Quantification of residual aortic regurgitation through contrast phase sequences.Delayed enhancement inversion recovery sequences after administration of 0.2 mmol/kg of gadolinium: a) Beginning 10 min after gadolinium administration; b) four-chamber, two-chamber and short axis views acquisition; c) Analysis of the following parameters: Telediastolic left ventricular volume (mL/m^2^); telesystolic left ventricular volume (mL/m^2^); stroke volume (mL); left ventricular ejection fraction (%); cardiac mass (g/m^2^); segmentary wall width (mm); telediastolic right ventricular volume (mL/m^2^); telesystolic right ventricular volume (mL/m^2^); right ventricular stroke volume (ml); right ventricular ejection fraction (%); myocardial deformation parameters: strain, strain rate, shift, speed, torsion and torsion rate; longitudinal strain, radial strain and circumferencial strain; quantification of residual aortic regurgitation (regurgitant volume ml; regurgitant fraction, %); presence and degree of myocardial fibrosis: location (subendocardial, subepicardial, intramyocardial), total fibrotic mass (total grams and % of total left ventricular mass).[^1]

Inclusion criteria {#s2a}
------------------

The target population will include patients over 60 years of age with severe AS assessed by transthoracic echocardiography who successfully undergo TAVI following approval by the heart team. Patients must be capable of understanding, accepting and signing informed consent. Successful TAVI procedure will follow the Valve Academic Research Consortium-2 definition of 'device success'.[@R29]

Exclusion criteria {#s2b}
------------------

Patients presenting with any of the following conditions will be excluded from the study: mitral disease requiring intervention, ventricular ejection fraction below 40%, prior myocardial infarction or dilated cardiomyopathy, presence of magnetic resonance incompatibilities (ie, devices, morbid obesity or claustrophobia), use of drugs for RAS blockade within the last 3 months or intolerance, allergy or contraindication for their use, including glomerular filtration rate below 30 mL/min and persistent hypotension (defined as systolic or diastolic blood pressure \<100 or \<60 mm Hg, respectively.)

Objectives {#s2c}
----------

The primary aim is to analyse the impact of ramipril associated with conventional treatment following percutaneous aortic valve replacement in terms of reduction of cardiac mortality, heart failure admissions and cerebrovascular events at 3-year follow-up.

Secondary objectives include left ventricular remodelling determined by ventricular mass, fibrosis and ejection fraction as assessed by CMR. Also, functional capacity after 1 year will be analysed.

Statistical analysis {#s2d}
--------------------

Sample size estimation was based on former studies in patients with AS.[@R22] First, the study by Dahl *et al*[@R27] included 114 patients and evaluated left ventricular mass after 1 year under treatment or standard care with a significant greater reduction of mass in the active group. Analysis of these data suggests the need for at least 79 patients in each group. Second, the research by Goel *et al*[@R26] retrospectively included 1752 patients aiming to analyse the impact on mortality; a propensity score subanalysis including 594 patients reported a 5-year mortality rate of 10% in the active group and 22% in the control group. From these data we estimated that two groups with 150 patients each were necessary. In addition, in the Heart Outcome Prevention Evaluation Study,[@R30] ramipril was stopped in 7% of the patients due to persistent cough. Taking this into consideration and after fixing α and β errors of 0.05 and 0.20, respectively, we estimate a sample size of 336 patients for the RASTAVI Study (including 5% potential missing subjects).

We will use the C4-Study design pack (Glaxo Welcome, V.1.1) as an independent system for blocked randomisation with balance across groups and blocks of four and six patients that will be randomly selected.

Finally, statistical analysis for categorical variables will be expressed both as absolute values and percentages and for continuous variables as average and SD, median and IQR. Pearson's χ^2^ test and Fisher's exact test will be performed for comparisons between groups with qualitative variables, and Student's t-test or Mann-Whitney test for continuous variables. All P values will be bilateral and will be considered statistically significant when \<0.05. Statistical package SSPS V.23 will be used.

Analysis {#s2e}
--------

There is a growing use of TAVI in younger patients and it is expected to become the standard care for AS in the coming years. However, outcomes following TAVI are not benign at all. In this regard, consensus exists regarding the need for measures and therapies that improve the long-term results following percutaneous aortic valve replacement.

The development of left ventricular hypertrophy and fibrosis results in poor outcome in patients with AS[@R9] and the persistence of hypertrophy and diastolic dysfunction after surgical valve replacement increases mortality.[@R23] Likewise, we can assume a similar role of adverse remodelling following TAVI. Moreover, the common presence of other concomitant cardiovascular diseases such as diabetes mellitus or hypertension increases the risk for developing heart failure, reducing the quality of life and survival after TAVI, even in patients without previous myocardial infarction and with preserved left ventricular ejection fraction. For this reason, the first-year readmission rate for any reason (44%), and specifically due to heart failure (12%), still remains high.[@R31]

A putative beneficial effect of RAS blockade after aortic valve replacement has been explored in several studies. A retrospective work in 150 patients showed that RAS blockade reduced hospital admission and deaths.[@R25] Of note, this effect was independent of left ventricular ejection fraction and volumes, suggesting a benefit of RAS blockade in patients with normal ventricular function and dimensions. A propensity analysis in 1752 patients suggested a better outcome when RAS was pharmacologically blocked.[@R26] Both studies have important limitations, including their retrospective nature, the lenient inclusion criteria and the lack of information regarding type and dose of drugs given to the patients. Although some authors had suggested a drug class effect of RAS inhibitors, it is generally accepted that there is no such effect given the differences in lipophilia, half life, effect duration and other pharmacological properties. Ramipril presents a favourable clinical profile and excellent results in prior clinical trials. Yusuf *et al* demonstrated that ramipril could prevent adverse ventricular remodelling and reduce adverse events including death, myocardial infarction and stroke in patients with high cardiovascular risk and no ventricular dysfunction or heart failure.[@R30]

There is only one prospective study in the surgical setting, with 114 patients, in which candesartan (32 mg per day) was compared with a control group.[@R27] One year after valve replacement, a reduction in left ventricular mass was more pronounced in the active group. Also, one single study has analysed retrospectively the effects of RAS blockade in patients harbouring a TAVI device suggesting that this therapy could be associated with greater left ventricular mass index regression and reduced all-cause mortality.[@R32] However, any randomised trial has confirmed this hypothesis. The RASTAVI Study is the first formal attempt to clarify the role of RAS inhibitors in the prognosis of these patients.

Limitations include a potential risk of high unexpected cross-over that might force to increase the number of participating institutions. Also, the unblinded nature of the study for the treating specialist can represent a potential bias that will be addressed by external monitoring of all clinical records and independent central analysis of all imaging parameters by experts in cardiac imaging, unaware of the assignment of the patients.

In conclusion, patients with AS treated with TAVI are at risk for developing persistent left ventricular adverse remodelling, heart failure and, consequently, early mortality. The results of the RASTAVI Study will contribute to improve the management of patients after TAVI and, if the results are positive for the active group, may potentially increase the quality of life, reduce rehospitalisations and improve the long-term survival in this scenario.

Clinical events will be recorded and will be adjudicated by a scientific committee including a clinical cardiologist, an interventional cardiologist and a neurologist who will be blinded to the therapeutic group to which the patient belongs. External independent monitoring of the study will be performed. Anonymised samples and imaging tests will be stored with restricted access to the investigators of the study. Liability insurance will be provided for compensation to those who may potentially suffer harm from trial participation. Only the principal investigator of each participating institution will have access to the final trial data set.

10.1136/bmjopen-2017-020255.supp1

10.1136/bmjopen-2017-020255.supp2

10.1136/bmjopen-2017-020255.supp3

Supplementary Material
======================

###### Reviewer comments

###### Author\'s manuscript

**Contributors:** Hypothesis and study design: IJA-S, PC, JL, LHV-F, TS, RA, AR, JASR. Approval of the protocol and commitment to recruitment during the study duration: IJA-S, FDdH, JAF-D, JHA-B, MDT, AR, PJ-S, VS, EG-I, AJM-G, LN-F, MS, VAJ-D, BGdB, JASR. Imaging and clinical evaluation during the study duration: IJA-S, PC, FDdH, JAF-D, JHA-B, MDT, AR, PJ-S, VS, EG-I, AJM-G, LN-F, MS, VAJ-D, BGdB, JL, LHV-F, TS, RA, MDT, AR, JASR. Final approval of the manuscript of the study design: all authors.

**Funding:** Instituto de Salud Carlos III (Ministerio de Economía, Industria y Competitividad), grant number PI17/02237.

**Competing interests:** None declared.

**Patient consent:** Obtained.

**Ethics approval:** Insituto de Salud Carlos III (Ministry of Health). Local ethics committees have provided informed consent adhering to the directions of the Declaration of Helsinki and the legal dispositions 14/2007 and RD 1090/2015 regarding biomedical research.

**Provenance and peer review:** Not commissioned; externally peer reviewed.

[^1]: bTFE, balanced turbo field echo; ERO, effective orifice area; FIESTA, Fast imaging employing steady state; LV, left ventricle; LVOT, left ventricular outflow tract; NT-proBNP, N-termina pro-brain natriuretic peptide; NYHA, New York Heart Association; SSFP, steady-state free precession; TAPSE, tricuspid annular plane systolic excursion; T-Tn, T-Troponin; TrueFISP, True fast imaging with steady state precession; VTI, velocity-time integral.
